NTLA Add to watchlist $11.38 0.48 (-4.09%) Last updated: Jul 19, 2026 18:38
52-Week Range
$11.38
$7.95 $11.38 $28.25

Fundamentals Overview

Intellia Therapeutics, Inc. is near the low of its 52-week range with premium valuation, trending downward today.

Valuation premium

P/B 2.17 P/S 19.31

Risk (Beta)

1.77 — higher vol

BullzEye Analysis

Our composite tilts Sell on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Sell — 71% confidence Risk: High Volatility — Beta 1.77. Consider smaller position size due to higher beta.

Pressures (Sell):

Sentiment weakening (4 downgrades) · 3M vs S&P 500: -30% · 3M vs Healthcare sector: -32.8% · Beta 1.77 (elevated)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$1.28B
P/E (TTM)
N/A
EPS (TTM)
N/A
Dividend Yield
N/A
52-Week Range
$7.95 - $28.25
Volume vs Avg
N/A
Beta
1.77

About

Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Typ...
Sector: Healthcare
Headquarters: US
Employees: 377
IPO Date: May 2016
Beta: 1.77 (More volatile than market)

Ratings & Grades at a Glance

Overall rating: C+. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 13, Equal Weight: 2, Hold: 1, In Line: 1, Market Outperform: 3, Market Perform: 1, Neutral: 4, Outperform: 1, Peer Perform: 1, Sector Perform: 1, Sell: 1, Underperform: 1.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $-18.58; current price is $11.38. That’s a -263.4% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) N/A
PEG (TTM) N/A
P/B (TTM) 2.17
P/S (TTM) 19.31
Liquidity & enterprise
Current Ratio (TTM) 6.1
Quick Ratio (TTM) 6.1
Cash Ratio (TTM) 1.76
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) -5.97%
Gross margin (TTM) -1.54%
Operating margin (TTM) -6.37%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for NTLA.

Analyst Sentiment at a Glance

C+ Sentiment Weakening
Buy 13Equal Weight 2Hold 1In Line 1Market Outperform 3Market Perform 1Neutral 4Outperform 1Peer Perform 1Sector Perform 1Sell 1Underperform 1
1 upgrade, 4 downgrades
Price Target Consensus
Current $11.38
Median $21.00
Consensus $23.50
Low consensus $9.00
High consensus $49.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Wolfe Research downgrade Peer Perform Underperform 2026-07-16
Wedbush maintain Neutral Neutral 2026-07-10
Canaccord Genuity maintain Buy Buy 2026-06-16
Citizens maintain Market Outperform Market Outperform 2026-06-15
Wedbush maintain Neutral Neutral 2026-06-15
HC Wainwright & Co. maintain Buy Buy 2026-06-15
Bernstein maintain Market Perform Market Perform 2026-05-13
HC Wainwright & Co. maintain Buy Buy 2026-05-13
Canaccord Genuity maintain Buy Buy 2026-05-12
Wedbush maintain Neutral Neutral 2026-05-12
Goldman Sachs maintain Sell Sell 2026-04-28
Citizens maintain Market Outperform Market Outperform 2026-04-28
Canaccord Genuity maintain Buy Buy 2026-04-28
Morgan Stanley maintain Equal Weight Equal Weight 2026-04-28
Chardan Capital maintain Buy Buy 2026-04-27
Baird maintain Neutral Neutral 2026-04-27
Jones Trading upgrade Hold Buy 2026-03-04
Citizens maintain Market Outperform Market Outperform 2026-03-03
HC Wainwright & Co. maintain Buy Buy 2026-03-03
Canaccord Genuity maintain Buy Buy 2026-03-03
Wells Fargo maintain Equal Weight Equal Weight 2026-03-03
Leerink Partners maintain Outperform Outperform 2026-03-03
RBC Capital maintain Sector Perform Sector Perform 2026-03-03
Chardan Capital maintain Buy Buy 2026-03-02
Chardan Capital maintain Buy Buy 2026-02-27
HC Wainwright & Co. maintain Buy Buy 2026-01-28
Wolfe Research downgrade Outperform Peer Perform 2025-11-12
Evercore ISI Group downgrade Outperform In Line 2025-11-11
Jones Trading downgrade Buy Hold 2025-11-11
Truist Securities maintain Buy Buy 2025-11-10